ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 479
- Registration Number
- NCT02329327
- Locations
- 🇬🇧
Clinical Study Site, Stoke on Trent, United Kingdom
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02324049
Registry of Patients With Hypophosphatasia
- Conditions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT02306720
- Locations
- 🇬🇧
Research Site, Belfast, United Kingdom
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT02301624
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Completed
- Conditions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02293382
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
Terminated
- Conditions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02293408
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02273596
- Locations
- 🇬🇧
Clinical Trial Site, Birmingham, United Kingdom
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02245412
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Abramson Cancer Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02235493
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02193867
© Copyright 2024. All Rights Reserved by MedPath